Primary Hypercholesterolaemia: Ezetrol, administered alone, or with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.
Ezetrol, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B and non-HDL-C in patients with mixed hyperlipedemia.
Homozygous Familial Hypercholesterolaemia (HoFH): Ezetrol, administered with a statin, is indicated for patients with HoFH. Patients may also receive adjunctive treatments (eg, LDL apheresis).
Homozygous Sitosterolaemia (Phytosterolaemia): Ezetrol is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.